organoids

A new discussion in drug discovery circles argues that reproducibility standards need to be rethought for advanced 3D cell models, such as organoids and spheroids. Because these systems are more complex and variable than traditional 2D cultures, conventional reproducibility criteria may not apply, prompting calls for updated guidelines on how such experiments are validated and reported across laboratories.

The scientific community is discussing efforts to scale liquid chromatography–mass spectrometry for organoid research. Organoids, lab-grown miniature tissue models, produce small sample volumes that make standardized LC–MS analysis difficult, and researchers are exploring workflows and automation to handle larger studies. Advances here could accelerate drug testing and disease modeling by allowing proteomic analysis across many organoid samples at once.